
    
      The vaccine being tested in this study is called Tetravalent Dengue Vaccine (TDV). The study
      will assess the immunogenicity and safety on the co-administration of 9vHPV vaccine with TDV
      in healthy participants aged â‰¥9 to <15 years.

      The study will enroll approximately 614 healthy volunteers. Participants will be randomly
      assigned to one of the two treatment groups-

        -  Group 1

        -  Group 2

      All participants will receive recombinant 9-valent Human Papillomavirus Vaccine (9vHPV)
      intramuscular (IM) in combination with Dengue Tetravalent Vaccine (TDV) subcutaneous (SC)
      injection on Day 1 (Month 0 ) followed by 9vHPV on Day 90 (Month 3) and TDV on Day 180 (Month
      6) in Group 1. Participants will receive 9vHPV on Day 1 (Month 0) and Day 180 (Month 6) IM in
      Group 2.

      This multi-center trial will be conducted in Thailand. The overall time to participate in
      this study is 12 months. Participants will make multiple visits to the clinic, after last
      dose of study drug for a follow-up assessment.
    
  